Cargando…

Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy

Bacterial infections are the main infectious diseases and cause of death worldwide. Antibiotics are used to treat various infections ranging from minor to life-threatening ones. The dominant route to administer antibiotics is through oral delivery and subsequent gastrointestinal tract (GIT) absorpti...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ze-Liang, Zhao, Jun, Xu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719120/
https://www.ncbi.nlm.nih.gov/pubmed/33293809
http://dx.doi.org/10.2147/IJN.S279652
_version_ 1783619617721155584
author Wu, Ze-Liang
Zhao, Jun
Xu, Rong
author_facet Wu, Ze-Liang
Zhao, Jun
Xu, Rong
author_sort Wu, Ze-Liang
collection PubMed
description Bacterial infections are the main infectious diseases and cause of death worldwide. Antibiotics are used to treat various infections ranging from minor to life-threatening ones. The dominant route to administer antibiotics is through oral delivery and subsequent gastrointestinal tract (GIT) absorption. However, the delivery efficiency is limited by many factors such as low drug solubility and/or permeability, gastrointestinal instability, and low antibacterial activity. Nanotechnology has emerged as a novel and efficient tool for targeting drug delivery, and a number of promising nanotherapeutic strategies have been widely explored to overcome these obstacles. In this review, we explore published studies to provide a comprehensive understanding of the recent progress in the area of orally deliverable nano-antibiotic formulations. The first part of this article discusses the functions and underlying mechanisms by which nanomedicines increase the oral absorption of antibiotics. The second part focuses on the classification of oral nano-antibiotics and summarizes the advantages, disadvantages and applications of nanoformulations including lipid, polymer, nanosuspension, carbon nanotubes and mesoporous silica nanoparticles in oral delivery of antibiotics. Lastly, the challenges and future perspective of oral nano-antibiotics for infection disease therapy are discussed. Overall, nanomedicines designed for oral drug delivery system have demonstrated the potential for the improvement and optimization of currently available antibiotic therapies.
format Online
Article
Text
id pubmed-7719120
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77191202020-12-07 Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy Wu, Ze-Liang Zhao, Jun Xu, Rong Int J Nanomedicine Review Bacterial infections are the main infectious diseases and cause of death worldwide. Antibiotics are used to treat various infections ranging from minor to life-threatening ones. The dominant route to administer antibiotics is through oral delivery and subsequent gastrointestinal tract (GIT) absorption. However, the delivery efficiency is limited by many factors such as low drug solubility and/or permeability, gastrointestinal instability, and low antibacterial activity. Nanotechnology has emerged as a novel and efficient tool for targeting drug delivery, and a number of promising nanotherapeutic strategies have been widely explored to overcome these obstacles. In this review, we explore published studies to provide a comprehensive understanding of the recent progress in the area of orally deliverable nano-antibiotic formulations. The first part of this article discusses the functions and underlying mechanisms by which nanomedicines increase the oral absorption of antibiotics. The second part focuses on the classification of oral nano-antibiotics and summarizes the advantages, disadvantages and applications of nanoformulations including lipid, polymer, nanosuspension, carbon nanotubes and mesoporous silica nanoparticles in oral delivery of antibiotics. Lastly, the challenges and future perspective of oral nano-antibiotics for infection disease therapy are discussed. Overall, nanomedicines designed for oral drug delivery system have demonstrated the potential for the improvement and optimization of currently available antibiotic therapies. Dove 2020-12-01 /pmc/articles/PMC7719120/ /pubmed/33293809 http://dx.doi.org/10.2147/IJN.S279652 Text en © 2020 Wu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Wu, Ze-Liang
Zhao, Jun
Xu, Rong
Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy
title Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy
title_full Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy
title_fullStr Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy
title_full_unstemmed Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy
title_short Recent Advances in Oral Nano-Antibiotics for Bacterial Infection Therapy
title_sort recent advances in oral nano-antibiotics for bacterial infection therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719120/
https://www.ncbi.nlm.nih.gov/pubmed/33293809
http://dx.doi.org/10.2147/IJN.S279652
work_keys_str_mv AT wuzeliang recentadvancesinoralnanoantibioticsforbacterialinfectiontherapy
AT zhaojun recentadvancesinoralnanoantibioticsforbacterialinfectiontherapy
AT xurong recentadvancesinoralnanoantibioticsforbacterialinfectiontherapy